Recent Advances in Vaccine Adjuvants
The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Toll-like receptor recognizes bacterial DNA
Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K., et al. (2000) · Nature · doi:10.1038/35047123 · Cited by 6,491 · cited 1×
“It has recently been shown that cellular responses to CpG DNA are mediated by binding to TLR9 (38).”
BackgroundPushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508 · cited 1×
“The immunostimulatory effect was due to the presence of unmethylated CpG dinucleotides (36), which are under-represented, and methylated in vertebrate DNA.”
BackgroundApproaching the Asymptote? Evolution and Revolution in Immunology
Janeway, C. A. (1989) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1989.054.01.003 · Cited by 3,252 · cited 2×
“Hence, it can be argued that the role of adjuvants for recombinant vaccines is to ensure that the vaccine resembles infection closely enough to initiate a potent immune response (17,22).”
BackgroundInnate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434 · cited 1×
“In the last decade, alternative models of immunity have been established that emphasize the selective pressures on the host to induce a pro-inflammatory innate immune response after exposure to pathogen-associated molecular patterns (17,18) and tissue damage (19–21).”
BackgroundThe Instructive Role of Innate Immunity in the Acquired Immune Response
Fearon, D. T., & Locksley, R. M. (1996) · Science · doi:10.1126/science.272.5258.50 · Cited by 1,719 · cited 5×
“In addition, the innate immune system directs the balance of humoral and CMI (23), and adjuvants can control the type of acquired immune response induced (24).”
BackgroundInfluentialBretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,692 · cited 1×
“The dominant paradigm in immunology for several decades was that the immune system evolved to discriminate self from nonself (16).”
BackgroundSynthesis and assembly of hepatitis B virus surface antigen particles in yeast
Valenzuela, P., Medina, A., Rutter, W. J., Ammerer, G., & Hall, B. D. (1982) · Nature · doi:10.1038/298347a0 · Cited by 877 · cited 1×
“The first recombinant protein vaccine that was developed, HbsAg, was expressed in yeast as a particulate protein (123).”
BackgroundStoute, J. A., Slaoui, M., Heppner, D. G., Momin, P., Kester, K. E., Desmons, P., Wellde, B. T., Garçon, N., Krzych, U., Marchand, M., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701093360202 · Cited by 870 · cited 1×
“The adjuvant formulation (SBAS-2) subsequently showed protective efficacy against an experimental challenge in human volunteers exposed to infected mosquitoes, although protection was of short duration (72).”
Background
Cited by
Nanotechnology: Intelligent Design to Treat Complex Disease
Couvreur, P., & Vauthier, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0284-8 · Cited by 948
JIANG, W., GUPTA, R., DESHPANDE, M., & SCHWENDEMAN, S. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2004.09.003 · Cited by 478
Recent advances in the discovery and delivery of vaccine adjuvants
O'Hagan, D. T., & Valiante, N. M. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1176 · Cited by 434
Self-citationMitragotri, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1728 · Cited by 395
An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Facciolà, A., Visalli, G., Laganà, A., & Di Pietro, A. (2022) · Vaccines · doi:10.3390/vaccines10050819 · Cited by 316
Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy
Demento, S. L., Eisenbarth, S. C., Foellmer, H. G., Platt, C., Caplan, M. J., Mark Saltzman, W., Mellman, I., Ledizet, M., Fikrig, E., Flavell, R. A., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.034 · Cited by 290
“nd malaria, are poorly developed or simply unavailable [4,5].”
BackgroundAdjuvants: Classification,Modus Operandi, and Licensing
Apostólico, J. D. S., Lunardelli, V. A. S., Coirada, F. C., Boscardin, S. B., & Rosa, D. S. (2016) · Journal of Immunology Research · doi:10.1155/2016/1459394 · Cited by 287
Zaks, K., Jordan, M., Guth, A., Sellins, K., Kedl, R., Izzo, A., Bosio, C., & Dow, S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7335 · Cited by 242
Coccidioidomycosis: host response and vaccine development
Cox, R. A., & Magee, D. M. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.804-839.2004 · Cited by 205
Metadata
- Authors
- Singh, M., & O'Hagan, D. T.
- Venue
- Pharmaceutical Research
- Published
- 2002-06
- Volume
- 19
- Issue
- 6
- Pages
- 715-728
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1800786347
- Cited by
- 245
- References
- 173
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.